#	Pagina
attuale pagina	/open-h2020/projects/196497/index.html
-1	/open-h2020/projects/224929/index.html
-2	/open-h2020/projects/221033/index.html
-3	/open-h2020/projects/225409/index.html
-4	/open-h2020/projects/223085/index.html
-5	/open-h2020/projects/217574/index.html
-6	/open-h2020/projects/196385/index.html
-7	/open-h2020/projects/196923/index.html
-8	/open-h2020/projects/221268/index.html
-9	/open-h2020/projects/218497/index.html
-10	/open-h2020/projects/193357/index.html

Opendata, web and dolomites

PROTOCOL

New processing technology for colistmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

PROTOCOL project word cloud

Explore the words cloud of the PROTOCOL project. It provides you a very rough idea of what is the project "PROTOCOL" about.

resistant hereinafter perform alternative scaling verify risks antimicrobial medicine coupled staff economic phd pyrogenic markets agent chances multidrug advantages treatment thorough threatening post financial outstanding validation cidqo bactericidal drying colistimethate formulation ingredients maximize cms manufacturing sme custom negative commercial commercialized sodium practical lc instrument ms finish antibiotic aqueous plan evaporation freeze market actual chemical sterile price feasibility relies pathogens gram veterinary ultrafiltration energetic infections innovation form returns combination business founded delivered quality opportunity exploited expertise commercialization effect active supply life limitations pharmaceutical minimize solutions hplc final industrial 2012 good nosocomial viability

Project "PROTOCOL" data sheet

The following table provides information about the project.

Coordinator	CIDQO 2012 SL Organization address address: POLIGONO INDUSTRIAL CAN VERDALET CARRER D NAU 91 city: TORDERA postcode: 8490 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.cidqo.com/Noticias/News/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-05-01 to 2015-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CIDQO 2012 SL CIDQO 2012 SL Organization address address: POLIGONO INDUSTRIAL CAN VERDALET CARRER D NAU 91 city: TORDERA postcode: 8490 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (TORDERA)	coordinator	50˙000.00

Map

Project objective

Colistimethate Sodium (CMS hereinafter) is a rapidly bactericidal antimicrobial agent with a significant post-antibiotic effect against multidrug resistant Gram-negative pathogens. CMS represents a reliable alternative for the treatment of life-threatening nosocomial infections but today the market supply of CMS relies on industrial processes based on freeze drying of CMS aqueous solutions. This represents outstanding energetic costs that directly affect the final price of CMS. CIDQO is an SME founded in 2012 and its PhD staff has a wide expertise and know-how on the development and scaling-up of chemical processes, as well as on custom manufacturing of active pharmaceutical ingredients. CIDQO aims to undertake an innovation project to solve the current limitations of CMS supply, through the industrial validation of a new processing technology based on the combination of ultrafiltration and evaporation coupled to HPLC/LC-MS. The key market opportunity of the new processing technology relies on its ability to deliver a non-pyrogenic and sterile CMS formulation to be commercialized on the Pharmaceutical and Veterinary medicine markets, which will represent several advantages in terms of price and quality compared with the current commercial form. The overall plan to reach the market needs to be defined in the short term since the innovation process is next to finish. Phase 1 of SME Instrument represents a good opportunity to get the financial support required to perform a thorough market study not only to minimize risks but also to set up a business plan for commercialization. The main objective is to perform a thorough feasibility study to verify the practical and economic viability in Pharmaceutical and Veterinary markets of the CMS form to be delivered by the new processing technology. The actual market chances that can be exploited to maximize the economic returns will be analyzed and a detailed business plan will be developed.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROTOCOL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROTOCOL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)

S3D (2015)

Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.